Mcleod phenotype associated with a XK missense mutation without hematologic, neuromuscular, or cerebral involvement

Transfusion

Volumn 43, Issue 7, 2003, Pages 928-938

  Jung, Hans H ^a   Hergersberg, Martin ^b   Vogt, Marco ^b   Pahnke, Jens ^b   Treyer, Valerie ^b   Röthlisberger, Benno ^b   Kollias, Spyros S ^b   Russo, David ^b   Frey, Beat M ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; DNA; GLYCOPROTEIN; PROTEIN; RNA; UNCLASSIFIED DRUG; XK PROTEIN;

ACANTHOCYTOSIS; ADULT; ARTICLE; BINDING SITE; BLOOD GROUP; BLOOD GROUP KELL SYSTEM; BLOOD TRANSFUSION; CASE REPORT; DISEASE CARRIER; DNA SEQUENCE; ERYTHROCYTE; EXON; GENE DELETION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HEMATOLOGIC DISEASE; HUMAN; HYPERTRANSLUCENT LUNG; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; MALE; MISSENSE MUTATION; MUSCLE BIOPSY; MYOPATHY; NERVE DEGENERATION; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; NEUROMUSCULAR DISEASE; NONSENSE MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PROTEIN BINDING; SYMPTOM; WESTERN BLOTTING; X CHROMOSOME LINKED DISORDER;

AMINO ACID TRANSPORT SYSTEMS, NEUTRAL; BLOTTING, WESTERN; BRAIN DISEASES; CHOREATIC DISORDERS; CHROMOSOMES, HUMAN, X; HEMATOLOGIC DISEASES; HUMANS; IMMUNOHISTOCHEMISTRY; KELL BLOOD-GROUP SYSTEM; LINKAGE (GENETICS); MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MUTATION, MISSENSE; NEUROMUSCULAR DISEASES; PEDIGREE; PHENOTYPE; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SYNDROME; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0038307154     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2003.t01-1-00434.x     Document Type: Article

References (37)

1. Schwartz SA, Marsh WL, Symmans A, et al. «New» clinical features of McLeod syndrome. Transfusion 1982;22:404.
2. Hardie RJ, Pullon HW, Harding AE, et al. Neuroacanthocytosis. A clinical, haematological and pathological study of 19 cases. Brain 1991;114:13-49.
3. Jung HH, Hergersberg M, Kneifel S, et al. McLeod syndrome: a novel mutation, predominant psychiatric manifestations, and distinct striatal imaging findings. Ann Neurol 2001;49:384-92.
4. Danek A, Rubio JP, Rampoldi L, et al. McLeod neuroacanthocytosis: genotype and phenotype. Ann Neurol 2001;50:755-64.
5. Allen FH, Krabbe SMR, Corcoran PA. A new phenotype (McLeod) in the Kell blood-group system. Vox Sang 1961;6:555-60.
6. Marsh WL, Taswell HF, Oyen R, et al. Kx antigen of the Kell system and its relationship to chronic granulomatous disease. Evidence the Kx gene is X-linked. Transfusion 1975;15:527.
7. Wimer BM, Marsh WL, Taswell HF, et al. Haematological changes associated with the McLeod phenotype of the Kell blood group system. Br J Haematol 1977;36:219-24.
8. Swash M, Schwartz MS, Carter ND, et al. Benign X-linked myopathy with acanthocytes (McLeod syndrome). Its relationship to X-linked muscular dystrophy. Brain 1983;106:717-33.
9. Ho M, Chelly J, Carter N, et al. Isolation of the gene for McLeod syndrome that encodes a novel membrane transport protein. Cell 1994;77:869-80.
10. Russo D, Redman C, Lee S. Association of XK and Kell blood group proteins. J Biol Chem 1998;273:13950-6.
11. Russo D, Wu X, Redman CM, et al. Expression of Kell blood group protein in nonerythroid tissues. Blood 2000;96:340-6.
12. Jung HH, Russo D, Redman C, et al. Kell and XK immunohistochemistry in McLeod myopathy. Muscle Nerve 2001;24:1346-51.
13. Stanfield GM, Horvitz HR. The ced-8 gene controls the timing of programmed cell deaths in C. Elegans Mol Cell 2000;5:423-33.
14. Lee S, Lin M, Mele A, et al. Proteolytic processing of big endothelin-3 by the kell blood group protein. Blood 1999;94:1440-50.
15. Ho MF, Chalmers RM, Davis MB, et al. A novel point mutation in the McLeod syndrome gene in neuroacanthocytosis. Ann Neurol 1996;39:672-5.
16. Supple SG, Iland HJ, Barnett MH, et al. A spontaneous novel XK gene mutation in a patient with McLeod syndrome. Br J Haematol 2001;115:369-72.
17. Russo DC, Lee S, Reid ME, et al. Point mutations causing the McLeod phenotype. Transfusion 2002;42:287-93.
18. Feinberg TE, Cianci CD, Morrow JS, et al. Diagnostic tests for choreoacanthocytosis. Neurology 1991;41:1000-6.
19. Lee S, Wu X, Reid M, et al. Molecular basis of the Kell (K1) phenotype. Blood 1995;85:912-6.
20. Friston KJ, Holmes AP, Poline JB, et al. Analysis of fMRI time-series revisited. Neuroimage 1995;2:45-53.
21. Bicik I, Radanov BP, Schafer N, et al. PET with 18fluorodeoxyglucose and hexamethylpropylene amine oxime SPECT in late whiplash syndrome. Neurology 1998;51:345-50.
22. Mikolajczyk K, Szabatin M, Rudnicki P, et al. A JAVA environment for medical image data analysis: initial application for brain PET quantitation. Med Inform (Lond) 1998;23:207-14.
23. Pehta J, Panesar N, Huima T, et al. Unusual presentation of a McLeod individual. Transfusion 1992;32:19S.
24. Lee S, Russo D, Redman C. Functional and structural aspects of the Kell blood group system. Transfus Med Rev 2000;14:93-103.
25. Symmans WA, Shepherd CS, Marsh WL, et al. Hereditary acanthocytosis associated with the McLeod phenotype of the Kell blood group system. Br J Haematol 1979;42:575-83.
26. Bertelson CJ, Pogo AO, Chaudhuri A, et al. Localization of the McLeod locus (XK) within Xp21 by deletion analysis. Am J Hum Genet 1988;42:703-11.
27. Marsh WL, Marsh NJ, Moore A, et al. Elevated serum creatine phosphokinase in subjects with McLeod syndrome. Vox Sang 1981;40:403-11.
28. Witt TN, Danek A, Reiter M, et al. McLeod syndrome: a distinct form of neuroacanthocytosis. Report of two cases and literature review with emphasis on neuromuscular manifestations. J Neurol 1992;239:302-6.
29. Oechsner M, Buchert R, Beyer W, et al. Reduction of striatal glucose metabolism in McLeod choreoacanthocytosis. J Neurol Neurosurg Psychiatry 2001;70:517-20.
30. Daniels GL, Weinauer F, Stone C, et al. A combination of the effects of rare genotypes at the XK and KEL blood group loci results in absence of Kell system antigens from the red blood cells. Blood 1996;88:4045-50.
31. Hanaoka N, Yoshida K, Nakamura A, et al. A novel frameshift mutation in the McLeod syndrome gene in a Japanese family. J Neurol Sci 1999;165:6-9.
32. Ueyama H, Kumamoto T, Nagao S, et al. A novel mutation of the McLeod syndrome gene in a Japanese family. J Neurol Sci 2000;176:151-4.
33. Lee S, Russo D, Redman CM. The Kell blood group system. Kell and XK membrane proteins. Semin Hematol 2000;37:113-21.
34. Kataoka Y, Koizumi S, Kohzuma M, et al. NMDA receptor involvement in endothelin neurotoxicity in rat striatal slices. Eur J Pharmacol 1995;273:285-9.
35. Ehrenreich H, Nau TR, Dembowski C, et al. Endothelin b receptor deficiency is associated with an increased rate of neuronal apoptosis in the dentate gyrus. Neuroscience 2000;95:993-1001.
36. Hackam AS, Yassa AS, Singaraja R, et al. Huntingtin interacting protein 1 induces apoptosis via a novel caspase-dependent death effector domain. J Biol Chem 2000;275:41299-308.
37. Gervais FG, Singaraja R, Xanthoudakis S, et al. Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi. Nat Cell Biol 2002;4:95-105.